Patrick Heron - Collegium Pharmaceutical Independent Director
| COLL Stock | USD 37.51 0.27 0.71% |
Director
Mr. Patrick J. Heron is a Independent Director of Collegium Pharmaceutical Inc. He is a General Partner of Frazier Management, LLC, or Frazier, a position he has held since September 1999. Mr. Heron was active in company formations and initial investments in various biotechnology companies, including Marcadia Biotech Inc., Calixa Therapeutics, Inc. and VentiRx Pharmaceuticals, Inc. Mr. Heron also led Frazier involvement in MedPointe Inc. Prior to joining Frazier, Mr. Heron helped develop McKinsey Co. west coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales force optimization, corporate partnering and research prioritization
| Age | 44 |
| Professional Marks | MBA |
| Address | 100 Technology Center Drive, Stoughton, MA, United States, 02072 |
| Phone | 781 713 3699 |
| Web | https://www.collegiumpharma.com |
Collegium Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1028 % which means that it generated a profit of $0.1028 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2468 %, meaning that it created $0.2468 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.09 this year. Return On Capital Employed is expected to rise to 0.26 this year. At this time, Collegium Pharmaceutical's Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.04 this year, although the value of Other Assets will most likely fall to about 21.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| John Martin | Deciphera Pharmaceuticals LLC | 57 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Dennis Walsh | Deciphera Pharmaceuticals LLC | 50 | |
| Michael Ross | Deciphera Pharmaceuticals LLC | 68 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Liam Ratcliffe | Deciphera Pharmaceuticals LLC | 53 | |
| James Bristol | Deciphera Pharmaceuticals LLC | 71 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Patricia Allen | Deciphera Pharmaceuticals LLC | 56 | |
| Susan Kelley | Deciphera Pharmaceuticals LLC | 63 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
Management Performance
Collegium Pharmaceutical Leadership Team
Elected by the shareholders, the Collegium Pharmaceutical's board of directors comprises two types of representatives: Collegium Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Collegium. The board's role is to monitor Collegium Pharmaceutical's management team and ensure that shareholders' interests are well served. Collegium Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Collegium Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bart Dunn, Executive Development | ||
| Richard Malamut, Chief Medical Officer | ||
| Paul Brannelly, CFO and Executive VP | ||
| Scott Sudduth, Head Operations | ||
| Christopher MD, Vice Relations | ||
| David Hirsch, Independent Director | ||
| John Fallon, Independent Director | ||
| RPh Pharm, CoFounder Chairman | ||
| Alex Dasalla, Head Relations | ||
| Michael Heffernan, Chairman of the Board and Presidentident, CEO | ||
| MD FAAFP, Executive Officer | ||
| John Freund, Independent Director | ||
| Eran Nadav, Independent Director | ||
| Alison Fleming, Vice President of Product Development | ||
| Steven Passik, Vice President - Scientific Affairs, Education and Policy | ||
| John Weet, Vice President - Regulatory Affairs and Quality Assurance | ||
| Garen Bohlin, Independent Director | ||
| Scott Dreyer, Executive Vice President Chief Commercial Officer | ||
| Marlo Manning, Head HR | ||
| Joseph Ciaffoni, COO, Executive Vice President | ||
| Colleen Tupper, Executive CFO | ||
| Richard MD, Ex Officer | ||
| Patrick Heron, Independent Director | ||
| Ernest Kopecky, Vice President - Clinical Development and Head of Neuroscience | ||
| Gino Santini, Independent Director | ||
| Gwen Melincoff, Director | ||
| Barry Duke, Chief Commercial Officer and Executive VP | ||
| Said Saim, Vice President of Pharmaceutical Development | ||
| Douglas Carlson, VP of Corporate Devel. | ||
| Theodore Schroeder, Director | ||
| Kevin OKeeffe, Vice President - Market Access and Trade | ||
| Shirley Kuhlmann, Executive Vice President General Counsel, Secretary |
Collegium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Collegium Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.41 % | ||||
| Current Valuation | 1.57 B | ||||
| Shares Outstanding | 32.71 M | ||||
| Shares Owned By Insiders | 1.41 % | ||||
| Shares Owned By Institutions | 98.59 % | ||||
| Number Of Shares Shorted | 6.99 M | ||||
| Price To Earning | 28.80 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Collegium Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Collegium Pharmaceutical's short interest history, or implied volatility extrapolated from Collegium Pharmaceutical options trading.
Pair Trading with Collegium Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collegium Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collegium Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Collegium Stock
| 0.71 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
| 0.55 | LCID | Lucid Group Earnings Call This Week | PairCorr |
| 0.52 | MHUA | Meihua International | PairCorr |
| 0.52 | PDEX | Pro Dex | PairCorr |
The ability to find closely correlated positions to Collegium Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collegium Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collegium Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collegium Pharmaceutical to buy it.
The correlation of Collegium Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collegium Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collegium Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collegium Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Collegium Stock analysis
When running Collegium Pharmaceutical's price analysis, check to measure Collegium Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collegium Pharmaceutical is operating at the current time. Most of Collegium Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Collegium Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collegium Pharmaceutical's price. Additionally, you may evaluate how the addition of Collegium Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Collegium Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 51.976 | Earnings Share 1.29 | Revenue Per Share 16.797 | Quarterly Revenue Growth 0.155 | Return On Assets 0.1028 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.